Farewell to the decade-long era of foreign investment, Guangyao takes over Nanjing Pharmaceutical—how much room for imagination does this open up?

Ask AI · How Guangzhou Pharmaceutical Achieves Complementarity Between the South China and East China Markets?

Produced by | China Visit Net

Reviewed by | Li Xiaoyan

On March 17, Nanjing Pharmaceutical announced a board resolution. The alignment of personnel adjustments with shareholder changes has attracted significant industry attention. This adjustment was driven by Alliance Healthcare, a subsidiary of the foreign investor Wobelin, fully exiting by selling its stake, and Guangzhou Pharmaceutical Group officially becoming the second-largest shareholder. This is not only an inevitable result of optimizing the equity structure but also a crucial step in the strategic alliance between two regional pharmaceutical distribution leaders and a move toward high-quality development. Although a minor incident occurred at the board meeting—some abstention votes—the overall personnel and equity changes were compliant and orderly, with a clear strategic direction. This solidifies the company’s long-term foundation and sets a high-quality example for industry consolidation in China’s pharmaceutical distribution sector.

The core background of this adjustment is the successful conclusion of Nanjing Pharmaceutical’s decade-long foreign-invested cooperation phase. In 2014, Nanjing Pharmaceutical introduced Alliance Healthcare, an international pharmaceutical retail giant under Wobelin, initiating a Sino-foreign partnership with 11.04% equity. The goal was to learn from international advanced management practices and promote industry upgrading. Over ten years, foreign directors and senior management contributed expertise to improve corporate governance and facilitate mergers and acquisitions. Mr. Luo Xunjie, a seasoned executive with experience in Fortune 500 companies, has dedicated nearly a decade to the company’s operations. His professional skills and contributions are highly regarded. With the completion of the equity transfer on February 26, 2026, Alliance Healthcare transferred all its shares, and the strategic cooperation agreement was terminated. The foreign nominees and executives stepped down in accordance with regulations, consistent with corporate governance rules and customary business practices. This is a normal, market-driven, and legal transition.

At the board meeting, Mr. Luo Xunjie abstained from voting on three proposals related to his own positions, which outsiders interpreted as a “silent stance.” From a corporate governance perspective, related directors voting cautiously on proposals involving their own interests and expressing independent opinions reflects their duties as directors. It did not prevent the proposals from passing lawfully nor hinder the company’s decision-making process. The absence of foreign director Marco Kerschen was also a normal arrangement following shareholder changes. This adjustment strictly followed the Company Law, the Articles of Association, and the strategic cooperation agreement. All six proposals were approved smoothly, and the board’s operation was standardized and effective, demonstrating mature and stable governance.

Guangzhou Pharmaceutical Group’s strategic entry is the most notable highlight of this adjustment, representing a strategic choice to leverage the strengths of both regional leaders for mutual development. As the leading pharmaceutical distributor in South China, Guangzhou Pharmaceutical ranked sixth nationwide among pharmaceutical distribution wholesalers in 2024. It has long focused on the South China market. In the first half of 2025, regional revenue reached RMB 31.19 billion, with strong regional barriers but some shortcomings in East China deployment. Nanjing Pharmaceutical, a leading enterprise in East China distribution, ranked seventh nationwide, with a network covering nearly 70 cities in Jiangsu, Anhui, Fujian, and Hubei, forming a perfect regional complement with Guangzhou Pharmaceutical. In this transaction, Guangzhou Pharmaceutical acquired shares for RMB 749 million, which is not only a financial investment but also the start of deep industrial collaboration. It fills the gap in Guangzhou Pharmaceutical’s presence in the Yangtze River Delta and supports its “South China + East China” dual-core expansion.

The appointment of new director candidate Mr. Chen Guangyan provides strong assurance for the implementation of both parties’ strategies. As a veteran from Guangzhou Pharmaceutical, Mr. Chen Guangyan joined Guangzhou Pharmaceutical Factory in 1988, rising from a frontline technician to Chairman of Guangzhou Pharmaceutical. With over 30 years of comprehensive management experience across production, quality control, distribution, and investment, he is well-versed in core business areas. His joining Nanjing Pharmaceutical’s board signifies Guangzhou Pharmaceutical’s deeper involvement in corporate governance, promoting rapid implementation of strategies such as supply chain integration, channel sharing, and product category synergy, and building a key bridge for resource sharing and cost efficiency.

Currently, China’s pharmaceutical distribution industry is in a critical period of rapid concentration. Policies like the “Two-Vote System” and normalization of centralized procurement are pushing the industry from fragmented competition toward scale-based dominance. Leading companies are expanding through mergers and acquisitions, while smaller players are exiting quickly. National champions such as Sinopharm, CR Vanguard, and Shanghai Pharmaceuticals are leading the way, and regional leaders must band together to grow larger and seize opportunities in the reshuffle. The partnership between Guangzhou Pharmaceutical and Nanjing Pharmaceutical breaks the traditional model of “national champions acquiring regional firms,” creating a new path for horizontal regional consolidation. This aligns with the strategic goal of “recreating a new Guangzhou Pharmaceutical” and helps Nanjing Pharmaceutical overcome regional bottlenecks and enhance its national competitiveness.

From an operational perspective, this integration will generate multiple benefits. In channel synergy, both sides will connect core markets in South China and East China, greatly improving coverage and delivery efficiency, while scale effects will reduce operational costs and address the historically low gross margins in distribution. Business synergy will enable Guangzhou Pharmaceutical’s Dahnan and healthcare products to quickly enter East China via Nanjing Pharmaceutical’s channels, and Nanjing Pharmaceutical can optimize its product mix using Guangzhou Pharmaceutical’s industrial resources. Digital collaboration will involve sharing supply chain digital technologies to upgrade warehousing, logistics, and terminal management, aligning with high-quality industry development. For Nanjing Pharmaceutical, moving beyond the foreign-invested cooperation phase and embracing local industry leaders better matches China’s market development logic, helping focus on domestic demand, optimize strategies, and reverse recent slight profit declines.

Of course, short-term challenges such as team integration, cross-regional operational efficiency, and strategy implementation will require time and patience. However, industry cases like CR Vanguard’s acquisition of Tasly have shown that market-driven integration and professional management can achieve win-win outcomes for shareholders, the company, and employees. With the advantages of state-owned enterprise governance and mature industry foundations, Guangzhou Pharmaceutical and Nanjing Pharmaceutical are capable of smoothly navigating the integration period and unlocking “1+1>2” synergy effects.

A decade of successful Sino-foreign cooperation has concluded, and local industry leaders are embarking on a new journey together. The equity and management adjustments at Nanjing Pharmaceutical are rational responses to industry trends and resource optimization. Minor incidents like abstention votes do not undermine the overall strategic correctness or compliance. Guangzhou Pharmaceutical’s deep involvement injects local industrial resources and momentum into Nanjing Pharmaceutical and sets a benchmark for regional industry integration. In the future, as South China and East China markets become more integrated and supply chains and channels coordinate fully, these two leaders are expected to work together to challenge the top tier of the industry, build a trillion-yuan pharmaceutical distribution giant, and accelerate China’s pharmaceutical distribution toward scale, professionalism, and digitalization—demonstrating greater responsibility in implementing the Healthy China strategy.